AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the “Company” or “Anebulo”), today announced financial results for the three months ended December 31, 2022 and recent updates. Second Quarter Fiscal Year 2023 and Subsequent Highlights: Completed dosing its randomized, double-blind, placebo-controlled Phase 2 trial evalua
The informative cannabis social network. Join groups, make friends and be part of the cannabis community! Share your recipes, product & strain reviews, tutorials and more! Log in or register to continue
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates
Stock Ticker
- Loading stock data...
Categories
Recent Posts
- Leafly Named Best B2C Cannabis Technology Platform
- Quill Continues to Grow Nationwide Footprint with Sizeable New Partnerships Spanning Businesses Across Multiple Industries
- Aelis Farma Publishes Half-Year Financial Results for 2023 and Confirms Its Development Objectives
- Leafly Challenges Certain New York Cannabis Regulations; Court Enters Order Blocking Enforcement
- Green Check Honored With PBC Top Compliance Company Award
More from this user
